Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
A Phase 1/2, Single Arm Study To Assess the Efficacy and Safety of Rigosertib (ON 01910.Na) Administered as 72-Hour and 120-Hour Continuous Intravenous Infusions Every Other Week for Two Cycles Then as Twice Daily Oral Capsules Given Continuously in Patients With Relapsed/Refractory Acute Myeloid or Lymphocytic Leukemia or Transformed Myeloproliferative Neoplasms
Status: Enrolling
Updated:  9/4/2012
The University of Texas M. D. Anderson Cancer Center
mi
from
Houston, TX
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
A Phase 1/2, Single Arm Study To Assess the Efficacy and Safety of Rigosertib (ON 01910.Na) Administered as 72-Hour and 120-Hour Continuous Intravenous Infusions Every Other Week for Two Cycles Then as Twice Daily Oral Capsules Given Continuously in Patients With Relapsed/Refractory Acute Myeloid or Lymphocytic Leukemia or Transformed Myeloproliferative Neoplasms
Status: Enrolling
Updated: 9/4/2012
The University of Texas M. D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies
Status: Enrolling
Updated:  9/8/2012
University of Alabama in Birmingham BMT/CT Program Outpatient Clinic
mi
from
Birmingham, AL
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies
Status: Enrolling
Updated: 9/8/2012
University of Alabama in Birmingham BMT/CT Program Outpatient Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated:  9/10/2012
California Cancer Associates
mi
from
Fresno, CA
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated: 9/10/2012
California Cancer Associates
mi
from
Fresno, CA
Click here to add this to my saved trials
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated:  9/10/2012
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated: 9/10/2012
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated:  9/10/2012
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated: 9/10/2012
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated:  9/10/2012
Wilshire Oncology Medical Group
mi
from
Corona, CA
Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions
Status: Enrolling
Updated: 9/10/2012
Wilshire Oncology Medical Group
mi
from
Corona, CA
Click here to add this to my saved trials
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated:  9/11/2012
Dana Farber
mi
from
Boston, MA
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated: 9/11/2012
Dana Farber
mi
from
Boston, MA
Click here to add this to my saved trials
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated:  9/11/2012
Mount Sinai Hospital
mi
from
New York, NY
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated: 9/11/2012
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated:  9/11/2012
NYU Clinical Cancer Center
mi
from
New York, NY
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated: 9/11/2012
NYU Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated:  9/11/2012
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated: 9/11/2012
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated:  9/11/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated: 9/11/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated:  9/11/2012
Saint Francis Hospital
mi
from
Greenville, SC
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
Status: Enrolling
Updated: 9/11/2012
Saint Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/14/2012
Clinical Research Facility
mi
from
La Jolla, CA
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/14/2012
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/14/2012
Clinical Research Facility
mi
from
Los Angeles, CA
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/14/2012
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/14/2012
Clinical Research Facility
mi
from
Pleasant Hill, CA
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/14/2012
Clinical Research Facility
mi
from
Pleasant Hill, CA
Click here to add this to my saved trials
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/14/2012
Clinical Research Facility
mi
from
Santa Maria, CA
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/14/2012
Clinical Research Facility
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/14/2012
Clinical Research Facility
mi
from
Bethesda, MD
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/14/2012
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Evaluation of Plerixafor (Mozobil ™, AMD3100) in Combination With Chemotherapy and G-CSF for CD34+ Cell Mobilization
Status: Enrolling
Updated:  9/18/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Evaluation of Plerixafor (Mozobil ™, AMD3100) in Combination With Chemotherapy and G-CSF for CD34+ Cell Mobilization
Status: Enrolling
Updated: 9/18/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
A Phase I Dose Escalation Trial of Clofarabine in Addition to Topotecan, Vinorelbine, Thiotepa, and Dexamethasone in Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Enrolling
Updated:  9/19/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
A Phase I Dose Escalation Trial of Clofarabine in Addition to Topotecan, Vinorelbine, Thiotepa, and Dexamethasone in Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status: Enrolling
Updated: 9/19/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  9/26/2012
Univerity of Chicago
mi
from
Chicago, IL
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 9/26/2012
Univerity of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  9/26/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 9/26/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  9/26/2012
Washington University at St. Louis Siteman Cancer Center
mi
from
St Louis, MO
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 9/26/2012
Washington University at St. Louis Siteman Cancer Center
mi
from
St Louis, MO
Click here to add this to my saved trials
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  9/26/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 9/26/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  9/26/2012
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 9/26/2012
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  9/26/2012
Temple University at Jeanes Hospital
mi
from
Philadelphia, PA
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 9/26/2012
Temple University at Jeanes Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Status: Enrolling
Updated:  9/30/2012
Providence Holy Cross Medical Center Providence
mi
from
Mission Hills, CA
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Status: Enrolling
Updated: 9/30/2012
Providence Holy Cross Medical Center Providence
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Status: Enrolling
Updated:  9/30/2012
Fox Valley Hematology and Oncology Fox Valley Hem & Onc (SC)
mi
from
Appleton, WI
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Status: Enrolling
Updated: 9/30/2012
Fox Valley Hematology and Oncology Fox Valley Hem & Onc (SC)
mi
from
Appleton, WI
Click here to add this to my saved trials
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Status: Enrolling
Updated:  9/30/2012
Medical College of Wisconsin (MCW)
mi
from
Milwaukee, WI
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.
Status: Enrolling
Updated: 9/30/2012
Medical College of Wisconsin (MCW)
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated:  10/4/2012
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated: 10/4/2012
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated:  10/4/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated: 10/4/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Aurora, CO
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Boston, MA
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Newark, NJ
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Post-transplant Cyclophosphamide and Sirolimus Following RIC Transplant
A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  10/8/2012
Northside Hospital
mi
from
Atlanta, GA
Post-transplant Cyclophosphamide and Sirolimus Following RIC Transplant
A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 10/8/2012
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of Arizona Univ Arizona
mi
from
*see Various Departments*, AZ
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of Arizona Univ Arizona
mi
from
*see Various Departments*, AZ
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of Arkansas/ Arkansas Cancer Research Center UAMS
mi
from
Little Rock, AR
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of Arkansas/ Arkansas Cancer Research Center UAMS
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of California Irvine University of California Irvin
mi
from
Orange, CA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of California Irvine University of California Irvin
mi
from
Orange, CA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
cCare Encinitas Location
mi
from
San Diego, CA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
cCare Encinitas Location
mi
from
San Diego, CA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of California San Deigo - Moores Cancer Dept. of Moores Cancer Center
mi
from
San Diego, CA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of California San Deigo - Moores Cancer Dept. of Moores Cancer Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Emory University School of Medicine/Winship Cancer Institute Emory 3
mi
from
Atlanta, GA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Emory University School of Medicine/Winship Cancer Institute Emory 3
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Georgia Health Sciences University Georgia Health 2
mi
from
Augusta, GA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Georgia Health Sciences University Georgia Health 2
mi
from
Augusta, GA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University Chicago Hospital Dept. of Univ of Chicago (2)
mi
from
Chicago, IL
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University Chicago Hospital Dept. of Univ of Chicago (2)
mi
from
Chicago, IL
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Indiana University Indiana Univ 2
mi
from
Indianapolis, IN
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Indiana University Indiana Univ 2
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Stormont Vail Healthcare - Cotton-O'Neil Clinic Stormont-Vail
mi
from
Topeka, KA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Stormont Vail Healthcare - Cotton-O'Neil Clinic Stormont-Vail
mi
from
Topeka, KA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Hematology and Oncology Specialists Dept of Hem&Onc Specialist - 2
mi
from
Metairie, LA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Hematology and Oncology Specialists Dept of Hem&Onc Specialist - 2
mi
from
Metairie, LA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Dana Farber Cancer Institute DFCI LG100
mi
from
Boston, MA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Dana Farber Cancer Institute DFCI LG100
mi
from
Boston, MA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University Missouri Ellis Fischel Cancer Center Univ Missouri
mi
from
Columbia, MO
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University Missouri Ellis Fischel Cancer Center Univ Missouri
mi
from
Columbia, MO
Click here to add this to my saved trials